NCT03734029 2025-10-06Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]Daiichi SankyoPhase 3 Active not recruiting557 enrolled 22 charts 2 FDA
NCT05722015 2025-09-11MK-3475A-D77Merck Sharp & Dohme LLCPhase 3 Active not recruiting377 enrolled 17 charts 2 FDA
NCT05257408 2025-04-16Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerCorcept TherapeuticsPhase 3 Active not recruiting381 enrolled 3 FDA